Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

February 8, 2024

Study Completion Date

February 16, 2024

Conditions

Wilson's Disease

Interventions

DRUG

900mg TETA 4HCl Once Daily Formulation

3x300mg trientine base tablets as a single AM dose

DRUG

900mg TETA 4HCl Cuprior®

6 x150mg trientine base tablets in two equally divided doses

Trial Locations (1)

Richmond Pharmacology Ltd, London